Literature DB >> 9545350

Properties of pervanadate and permolybdate. Connexin43, phosphatase inhibition, and thiol reactivity as model systems.

S O Mikalsen1, O Kaalhus.   

Abstract

Pervanadate and permolybdate are irreversible protein-tyrosine phosphatase inhibitors, with IC50 values of 0.3 and 20 microM, respectively, in intact cells. Maximal inhibition was obtained within 1 min at higher concentrations of the compounds. They induced prominent changes in the phosphorylation status of the gap junction protein, connexin43. These effects were utilized as model systems to assess the stability and inactivation of the compounds. Although the concentrated stock solutions were relatively stable, the diluted compounds were unstable. The biological activity had decreased to 20-30% after 6 h of incubation in a phosphate buffer, 1 h in phosphate buffer with 10% fetal calf serum, and 1-3 minutes in culture medium. Thiols reacted rapidly with the compounds and inactivated them (initial reaction rates with cysteine: permolybdate > pervanadate > H2O2). Catalase inactivated the compounds, and permolybdate was the more sensitive. The cells inactivated permolybdate faster than pervanadate. Cellular inactivation of permolybdate, and to a lesser degree pervanadate, appeared to be partly dependent on catalase and thiols. However, a general decrease in cellular thiols was not the mediator of the biological effects of pervanadate or permolybdate. Mathematical modeling of the thiol reactivity suggested that monoperoxovanadate at maximum could possess 20% of the biological activity of diperoxovanadate.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9545350     DOI: 10.1074/jbc.273.16.10036

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

1.  In situ analysis of tyrosine phosphorylation networks by FLIM on cell arrays.

Authors:  Hernán E Grecco; Pedro Roda-Navarro; Andreas Girod; Jian Hou; Thomas Frahm; Dina C Truxius; Rainer Pepperkok; Anthony Squire; Philippe I H Bastiaens
Journal:  Nat Methods       Date:  2010-05-09       Impact factor: 28.547

2.  Down-regulation of protein-tyrosine phosphatases activates an immune receptor in the absence of its translocation into lipid rafts.

Authors:  Petr Heneberg; Lubica Dráberová; Monika Bambousková; Petr Pompach; Petr Dráber
Journal:  J Biol Chem       Date:  2010-02-15       Impact factor: 5.157

3.  Characterisation of the PTEN inhibitor VO-OHpic.

Authors:  Lok Hang Mak; Ramón Vilar; Rudiger Woscholski
Journal:  J Chem Biol       Date:  2010-06-04

4.  Pre-clinical evaluation of tyrosine kinase inhibitors for treatment of acute leukemia.

Authors:  Sandra Christoph; Alisa B Lee-Sherick; Susan Sather; Deborah DeRyckere; Douglas K Graham
Journal:  J Vis Exp       Date:  2013-09-18       Impact factor: 1.355

5.  The discovery of a reciprocal relationship between tyrosine-kinase signaling and cullin neddylation.

Authors:  Samantha F Friend; Lisa K Peterson; Eric Treacy; Adrianne L Stefanski; Tomasz Sosinowski; Nathan D Pennock; Allison J Berger; Virginia D Winn; Leonard L Dragone
Journal:  PLoS One       Date:  2013-10-04       Impact factor: 3.240

6.  A fully human inhibitory monoclonal antibody to the Wnt receptor RYK.

Authors:  Michael M Halford; Maria L Macheda; Clare L Parish; Elena A Takano; Stephen Fox; Daniel Layton; Edouard Nice; Steven A Stacker
Journal:  PLoS One       Date:  2013-09-18       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.